HUE034389T2 - Egy HIV proteáz-inhibitor pszeudopolimorf formái - Google Patents
Egy HIV proteáz-inhibitor pszeudopolimorf formái Download PDFInfo
- Publication number
- HUE034389T2 HUE034389T2 HUE14168686A HUE14168686A HUE034389T2 HU E034389 T2 HUE034389 T2 HU E034389T2 HU E14168686 A HUE14168686 A HU E14168686A HU E14168686 A HUE14168686 A HU E14168686A HU E034389 T2 HUE034389 T2 HU E034389T2
- Authority
- HU
- Hungary
- Prior art keywords
- compound
- pseudopolymorph
- ratio
- range
- ethanol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Claims (7)
- EGY IIIY mOTEÁZ4NBÍBII'OR PSZEUDÖPÍM JMCMM POMMAI SxafeaáaMpal Igesi^posslök I, A {3R.3aS>6»fl}>hexahidK)f\{ro(23>b|fbrfe-3-il{lS>2R}-'i-[[C4"am^n(-^cn^)s:'3!MWö{»fliÄ«^l aminol- I > ben?, t! -2 -hidroxi* propiíka rbamát egy etanolát pszeudopolimöríiöi: egy gyógyszerként történő alkalmazásra. Y -fecudopoHtnorf az i. igénypont szerűn, ahol a vegyületnek az aránya az et»te képes? s;í? (5:1) ás ( 1:5) közötti tartományban található
- 3. - Pszeudopolimoff az l. igénypont szerint, ahol a vegyületnek az aránya az etanolloz képes: a {{),2:1 ) és ¢3:1) közötti tartományban található,
- 4. Psze-udopolimotf az 1. igénypont szeri nh ahol a vegyületnek az aránya az· etanolhnz képest az {1 : l) és (2: \ ) közötti tartományban található.
- 5. Pszettdopolitnorf az 1, igénypont szerint, ahol a vegypletnek az aránya az «tanaihoz képest körülbelül 1:1. tk PszeudopolhnorΓ az I .-tol |<4g: igénypontok bármelyike szerint, amely továbbá tartalmaz vlzmolekulákat.
- 7, Pszcudopoítmotf az 1 ,-tôl 5. -ig igénypontok báPPÓlyiké: szerint, ahol a pszeitdopolímorf egy 90%-nál nagyobb tisztasággal rendelkezik, B, Pszeodopolimorf az l.-tói 5.-ig igénypontok bármelyike szerion ahbl &,;p$£é«ddpôh«K>rf egy 95%-nál nagyobb tisztasággá) rendelkezik. % Pszeudopohmoif az l.-töi 5.-ig igénypontok bámlélytke szerint, nbol b pszoudoiKübmyrb egy 993 o-nái nagyobb tisztasággal rendelkezik. löt A (3R,3aSí6aR)dx'Xidűdrofuro[2,3''b|l\írév3~il(lS,2Ro.''|(t4-.tnbnófentl}szu!öbnll)(izob«bI) amino}”l“benzil*2'hídroxi-propilkarbamát egy hidrát pszeudopollmörf)a, egy gyógyszerként történő aikaima.zásra, II, Pszeudopolhnorf a 10. igénypont szerint,. ahol a vegyöletnék matáipt· vliieiiMfóft az (5: Î) és í 1:5) közötti tartományban található.
- 12, Pszeudopolimorfa 10. igénypont szerint, ahol a yegy&tnek az aránya a ytíim képest a (0,2:1) és (3:1) között* tartományban található,
- 13, Pszeudopoümorí a 10, igénypont szerint, ahola vegyületnek az aránya a vízhez képest az ( 1:1 ) és (2:1 ) közötti tartományban található:. I4v Pszsudopóíisrtorf a M, üpnypont szerint, ahöl« vegyuletnek az aránya a vízhez képest körülbelül 1:1. Ili Pszeudopol i morf a Hh-nil :14,-1 g igénypontok bármelyike szerint, ahol a pszeudopotoorf ugv 90%-nái nagyobb tisztasággal rendelkezik. IC Fszeudopoümorf a 10,-tÖl 14,-ig igénypontok igénypontok bármelyike szerint, ahol a pszeudopoI imorf égy 95%-aáI nagyobb tiszt asággal: rendé1 kezik. 17, "Pszeudopolhnorf a. ib.-töi 14.-ig igénypontok bármolyike szerint, áhnl apszeudnpoltrnMf egy 99Vnál nagyobb tisztasággal rendelkezik,
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02076929 | 2002-05-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE034389T2 true HUE034389T2 (hu) | 2018-02-28 |
Family
ID=29724454
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE14168686A HUE034389T2 (hu) | 2002-05-16 | 2003-05-16 | Egy HIV proteáz-inhibitor pszeudopolimorf formái |
Country Status (26)
Country | Link |
---|---|
US (8) | US7700645B2 (hu) |
EP (4) | EP1567529B2 (hu) |
JP (1) | JP4864320B2 (hu) |
KR (2) | KR101128370B1 (hu) |
CN (1) | CN100475819C (hu) |
AP (1) | AP2052A (hu) |
AU (2) | AU2003271740B2 (hu) |
BR (1) | BRPI0311176B8 (hu) |
CA (1) | CA2485834C (hu) |
CY (3) | CY1117928T1 (hu) |
DK (3) | DK2767539T3 (hu) |
EA (1) | EA007120B8 (hu) |
ES (4) | ES2728735T3 (hu) |
HK (1) | HK1081969A1 (hu) |
HR (1) | HRP20041061B1 (hu) |
HU (1) | HUE034389T2 (hu) |
IL (1) | IL165140A0 (hu) |
LT (1) | LT2767539T (hu) |
MX (1) | MXPA04011427A (hu) |
NO (1) | NO331477B1 (hu) |
NZ (1) | NZ536497A (hu) |
PL (1) | PL215151B1 (hu) |
PT (3) | PT1567529E (hu) |
SI (3) | SI2314591T2 (hu) |
WO (1) | WO2003106461A2 (hu) |
ZA (1) | ZA200410154B (hu) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU771780B2 (en) | 1998-06-23 | 2004-04-01 | Board Of Trustees Of The University Of Illinois, The | Fitness assay and associated methods |
HUE034389T2 (hu) | 2002-05-16 | 2018-02-28 | Janssen Sciences Ireland Uc | Egy HIV proteáz-inhibitor pszeudopolimorf formái |
HRP20020614A2 (en) * | 2002-07-22 | 2004-06-30 | PLIVA-ISTRAŽIVAČKI INSTITUT d.o.o. | Rhombic pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin a |
US7772411B2 (en) | 2003-12-23 | 2010-08-10 | Tibotec Pharmaceuticals Ltd. | Process for the preparation of (3R,3aS,6aR)-hexahydrofuro [2,3-b] furan-3-yl (1S,2R)-3[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-hydroxypropylcarbamate |
WO2006089942A1 (en) | 2005-02-25 | 2006-08-31 | Tibotec Pharmaceuticals Ltd. | Protease inhibitor precursor synthesis |
DE602007012365D1 (de) * | 2006-11-09 | 2011-03-17 | Little Island Co Cork | Verfahren zur herstellung von hexahydrofuroä2,3-büfuran-3-ol |
AR073248A1 (es) | 2008-09-01 | 2010-10-20 | Tibotec Pharm Ltd | Proceso para la preparacion de (1s, 2r)-3- ((4-aminofenil) sulfonil) ( isobutil) amino)-1- bencil-2- hidroxipropilcarbamato de (3r, 3as,6ar)- hexahidrofuro-(2,3-b) furan-3- ilo (darunavir) y compuestos intermediarios utiles en dicho proceso. |
US20120035142A1 (en) * | 2009-01-29 | 2012-02-09 | Mapi Pharma Limited | Polymorphs of darunavir |
US8921415B2 (en) | 2009-01-29 | 2014-12-30 | Mapi Pharma Ltd. | Polymorphs of darunavir |
CA2776807C (en) * | 2009-09-17 | 2018-10-16 | Mylan Laboratories Limited | An improved process for the preparation of darunavir |
EP2493891A2 (en) | 2009-10-30 | 2012-09-05 | Lupin Limited | A novel process for preparation of darunavir and darunavir ethanolate of fine particle size |
US20110313035A1 (en) * | 2009-12-16 | 2011-12-22 | Hetero Research Foundation | Polymorphs of darunavir |
KR20120123077A (ko) * | 2010-01-05 | 2012-11-07 | 씨아이피엘에이 엘티디. | 다루나비르 다형체 및 그의 제조 방법 |
WO2011092687A1 (en) | 2010-01-28 | 2011-08-04 | Mapi Pharma Hk Limited | Process for the preparation of darunavir and darunavir intermediates |
CA2799762C (en) | 2010-05-20 | 2018-03-06 | Hetero Research Foundation | Crystalline hydrochloride salt of darunavir |
WO2012107889A1 (en) | 2011-02-10 | 2012-08-16 | Ranbaxy Laboratories Limited | Process for the preparation of amorphous darunavir |
HUE035241T2 (hu) | 2011-07-07 | 2018-05-02 | Janssen Sciences Ireland Uc | Darunavir kombinációs készítmények |
WO2013114382A1 (en) | 2011-12-05 | 2013-08-08 | Mylan Laboratories Ltd | Crystalline darunavir |
WO2013108105A2 (en) * | 2012-01-18 | 2013-07-25 | Aurobindo Pharma Limited | Novel solvates of darunavir |
CN103509031B (zh) * | 2012-06-20 | 2016-04-27 | 上海迪赛诺药业有限公司 | 制备达芦那韦无定形物的方法 |
WO2014016660A2 (en) | 2012-07-24 | 2014-01-30 | Laurus Labs Private Limited | A process for preparation of darunavir |
US9227990B2 (en) | 2012-10-29 | 2016-01-05 | Cipla Limited | Antiviral phosphonate analogues and process for preparation thereof |
US9346820B2 (en) * | 2013-09-11 | 2016-05-24 | Purdue Research Foundation | HIV-1 protease inhibitors having gem-di-fluoro bicyclic P2-ligands |
WO2016092525A1 (en) * | 2014-12-12 | 2016-06-16 | Lupin Limited | Darunavir n-propanol solvate and process for preparation thereof |
WO2016092527A1 (en) * | 2014-12-12 | 2016-06-16 | Sun Pharmaceutical Industries Limited | A process for the preparation of dolutegravir |
ES2926063T3 (es) | 2015-03-19 | 2022-10-21 | Mycovia Pharmaceuticals Inc | Compuestos antifúngicos y procedimientos de fabricación |
EP3496719B1 (en) | 2016-08-08 | 2023-06-14 | Hetero Labs Limited | A multi-class anti-retroviral composition |
WO2018029561A1 (en) | 2016-08-08 | 2018-02-15 | Hetero Labs Limited | Anti-retroviral compositions |
US10407438B2 (en) | 2016-10-27 | 2019-09-10 | Gilead Sciences, Inc. | Crystalline forms of darunavir |
CN108727401A (zh) * | 2017-04-20 | 2018-11-02 | 盐城迪赛诺制药有限公司 | 达鲁那韦新晶型及其制备方法和应用 |
CN109053753A (zh) * | 2018-08-05 | 2018-12-21 | 浙江大学 | 一种制备达卢那韦二水合物晶型的方法 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5413999A (en) * | 1991-11-08 | 1995-05-09 | Merck & Co., Inc. | HIV protease inhibitors useful for the treatment of AIDS |
JPH05230044A (ja) | 1992-02-21 | 1993-09-07 | Hoechst Japan Ltd | ピレタニドの新規な結晶多形 |
US5968942A (en) | 1992-08-25 | 1999-10-19 | G. D. Searle & Co. | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
ES2127938T3 (es) | 1993-08-24 | 1999-05-01 | Searle & Co | Hidroxietilamino sulfonamidas utiles como inhibidores de proteasas retroviricas. |
WO1996026197A1 (en) * | 1995-02-22 | 1996-08-29 | Hoechst Pharmaceuticals & Chemicals K.K. | Amorphous piretanide, piretanide polymorphs, process for their preparation and their use |
CO4940492A1 (es) * | 1997-05-29 | 2000-07-24 | Merck & Co Inc | Inhibidor de proteasa de vih |
GB9712253D0 (en) | 1997-06-13 | 1997-08-13 | Glaxo Group Ltd | Antiviral compound |
US6287693B1 (en) * | 1998-02-25 | 2001-09-11 | John Claude Savoir | Stable shaped particles of crystalline organic compounds |
GB9805898D0 (en) * | 1998-03-20 | 1998-05-13 | Glaxo Group Ltd | Process for the sythesis of hiv protease inhibitors |
GB9807354D0 (en) | 1998-04-07 | 1998-06-03 | Glaxo Group Ltd | Antiviral compound |
AU4828199A (en) * | 1998-06-23 | 2000-01-10 | Board Of Trustees Of The University Of Illinois, The | Multi-drug resistant retroviral protease inhibitors and associated methods |
AU771780B2 (en) * | 1998-06-23 | 2004-04-01 | Board Of Trustees Of The University Of Illinois, The | Fitness assay and associated methods |
US6225317B1 (en) | 1998-11-19 | 2001-05-01 | Dupont Pharmaceuticals Company | Crystalline (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-3,4-dihydro-2(1H)-quinazolinone |
AU3485800A (en) | 1999-02-12 | 2000-08-29 | Vertex Pharmaceuticals Incorporated | Inhibitors of aspartyl protease |
HUE034389T2 (hu) | 2002-05-16 | 2018-02-28 | Janssen Sciences Ireland Uc | Egy HIV proteáz-inhibitor pszeudopolimorf formái |
KR20120123077A (ko) * | 2010-01-05 | 2012-11-07 | 씨아이피엘에이 엘티디. | 다루나비르 다형체 및 그의 제조 방법 |
-
2003
- 2003-05-16 HU HUE14168686A patent/HUE034389T2/hu unknown
- 2003-05-16 DK DK14168686.5T patent/DK2767539T3/en active
- 2003-05-16 SI SI200332383T patent/SI2314591T2/sl unknown
- 2003-05-16 ES ES16158480T patent/ES2728735T3/es not_active Expired - Lifetime
- 2003-05-16 KR KR1020047018426A patent/KR101128370B1/ko active IP Right Grant
- 2003-05-16 EP EP03753571.3A patent/EP1567529B2/en not_active Expired - Lifetime
- 2003-05-16 EP EP16158480.0A patent/EP3045460B1/en not_active Expired - Lifetime
- 2003-05-16 PT PT37535713T patent/PT1567529E/pt unknown
- 2003-05-16 EA EA200401503A patent/EA007120B8/ru unknown
- 2003-05-16 PL PL374321A patent/PL215151B1/pl unknown
- 2003-05-16 PT PT101808319T patent/PT2314591E/pt unknown
- 2003-05-16 PT PT141686865T patent/PT2767539T/pt unknown
- 2003-05-16 CA CA002485834A patent/CA2485834C/en not_active Expired - Lifetime
- 2003-05-16 WO PCT/EP2003/050176 patent/WO2003106461A2/en active Application Filing
- 2003-05-16 LT LTEP14168686.5T patent/LT2767539T/lt unknown
- 2003-05-16 AU AU2003271740A patent/AU2003271740B2/en not_active Revoked
- 2003-05-16 AP AP2004003191A patent/AP2052A/xx active
- 2003-05-16 DK DK03753571.3T patent/DK1567529T4/da active
- 2003-05-16 JP JP2004513292A patent/JP4864320B2/ja not_active Expired - Lifetime
- 2003-05-16 DK DK10180831.9T patent/DK2314591T4/da active
- 2003-05-16 ES ES10180831T patent/ES2503551T5/es not_active Expired - Lifetime
- 2003-05-16 NZ NZ536497A patent/NZ536497A/en not_active IP Right Cessation
- 2003-05-16 MX MXPA04011427A patent/MXPA04011427A/es active IP Right Grant
- 2003-05-16 EP EP14168686.5A patent/EP2767539B1/en not_active Expired - Lifetime
- 2003-05-16 SI SI200332545T patent/SI2767539T1/sl unknown
- 2003-05-16 BR BRPI0311176A patent/BRPI0311176B8/pt active IP Right Grant
- 2003-05-16 KR KR1020107024106A patent/KR20100119906A/ko not_active Application Discontinuation
- 2003-05-16 SI SI200332389T patent/SI1567529T2/sl unknown
- 2003-05-16 CN CNB038164590A patent/CN100475819C/zh not_active Expired - Lifetime
- 2003-05-16 ES ES03753571T patent/ES2498370T5/es not_active Expired - Lifetime
- 2003-05-16 US US10/514,352 patent/US7700645B2/en active Active
- 2003-05-16 ES ES14168686.5T patent/ES2638412T3/es not_active Expired - Lifetime
- 2003-05-16 EP EP10180831.9A patent/EP2314591B2/en not_active Expired - Lifetime
-
2004
- 2004-11-10 IL IL16514004A patent/IL165140A0/xx unknown
- 2004-11-12 HR HRP20041061AA patent/HRP20041061B1/hr not_active IP Right Cessation
- 2004-12-10 NO NO20045409A patent/NO331477B1/no not_active IP Right Cessation
- 2004-12-15 ZA ZA2004/10154A patent/ZA200410154B/en unknown
-
2006
- 2006-02-23 HK HK06102443.3A patent/HK1081969A1/xx not_active IP Right Cessation
-
2009
- 2009-08-06 US US12/536,807 patent/US8518987B2/en not_active Expired - Lifetime
-
2012
- 2012-07-03 AU AU2012205289A patent/AU2012205289A1/en active Pending
-
2013
- 2013-07-11 US US13/939,494 patent/US20130303790A1/en not_active Abandoned
-
2014
- 2014-02-19 US US14/183,712 patent/US20140171499A1/en not_active Abandoned
- 2014-09-17 CY CY20141100756T patent/CY1117928T1/el unknown
- 2014-09-17 CY CY20141100755T patent/CY1115665T1/el unknown
-
2015
- 2015-08-04 US US14/817,827 patent/US20150336980A1/en not_active Abandoned
-
2017
- 2017-05-22 US US15/600,932 patent/US10000504B2/en not_active Expired - Lifetime
- 2017-08-23 CY CY20171100896T patent/CY1119311T1/el unknown
-
2018
- 2018-05-16 US US15/980,993 patent/US10858369B2/en not_active Expired - Lifetime
-
2020
- 2020-10-30 US US17/085,096 patent/US20210179631A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210179631A1 (en) | Pseudopolymorphic Forms of a HIV Protease Inhibitor | |
EP2548879B1 (en) | Crystal of diamine derivative and method of producing same | |
WO2015145415A2 (en) | Ibrutinib solid forms and production process therefor | |
WO2017072543A1 (en) | Palbociclib salts |